NLS drug-2

The last patient has now been included in the ongoing clinical study with ACD440, the lead non-opioid drug candidate in the painless platform, which is being developed against peripheral neuropathic pain. This double-blind, placebo-controlled, randomized cross-over study, which is carried out in collaboration with LINK Medical Research in Uppsala, is aimed at evaluating the efficacy, […]

Ultimovacs has announced the completed recruitment of 118 patients with pleural mesothelioma in the NIPU trial. NIPU is a randomized, multi-center phase II trial initiated and sponsored by Oslo University Hospital with support from Bristol-Myers Squibb and Ultimovacs. UV1 is being evaluated in combination with the checkpoint inhibitors ipilimumab and nivolumab as second-line treatment for patients with malignant pleural mesothelioma. The ipilimumab and […]

IRLAB Therapeutics has announced the results from the Phase IIb study of mesdopetam in people with Parkinson’s disease levodopa-induced dyskinesias (PD-LIDs). The primary endpoint, change in daily hours of ON-time without troublesome dyskinesia, as assessed with patient diaries, did not reach statistical significance by mesdopetam compared to placebo. “Unfortunately, the primary endpoint to increase “good […]

Ultimovacs has announced that cemiplimab (Libtayo) will be used as the PD-1 checkpoint inhibitor in combination with UV1 in the Phase II randomized LUNGVAC trial rather than pembrolizumab (Keytruda). The move, which will be implemented January 1, 2023, follows the decision by the Norwegian Health Authorities of reimbursement of cemiplimab for monotherapy or first-line treatment […]

Mendus has presented survival data based on the completed active study period and long-term follow-up to date from the ADVANCE II clinical trial at the American Society of Hematology Annual Meeting. ADVANCE II is a Phase 2 monotherapy trial evaluating DCP-001 as a maintenance therapy in acute myeloid leukemia (AML) for patients brought into complete […]

IRLAB Therapeutics has announced that the final patient has completed the treatment period and follow-up visit in the Phase IIb study of mesdopetam in levodopa-induced dyskinesia in people with Parkinson’s disease (PD-LIDs). The top-line results are expected to be reported in mid-January 2023, states the company in a press release. An oral dopamine D3 antagonist […]